Boardroom Alpha
Start trial
10-Q primary document
SNOA · Quarterly Report (Form 10-Q) · Filed February 10, 2026

Sonoma Pharmaceuticals Inc — 10-Q exhibit

sonoma_ex1018.htm
Sonoma Pharmaceuticals Inc on Boardroom Alpha

Exhibit 10.18

 

 

Lease Extension Agreement

 

This Second Amendment to the Lease (this “Second Amendment”) is made November 5, 2025, by and between WESTLAND DEVELOPMENT SERVICES, INC., a Colorado Corporation, (the “Landlord”), and SONOMA PHARMACEUTICALS, INC., a(n) Delaware Corporation (the “Tenant”).

 

RECITALS

 

A.The Landlord and the Tenant entered into that certain Lease, dated February 19, 2021 and a First Amendment to the Lease dated June 21, 2023 (collectively referred to as the “Lease”) with respect to the premises described therein (the “Premises”), covering approximately 2,766 square feet of the Premises, known as 5445 Conestoga Court, Unit(s)/Suite(s) (150), Boulder, Colorado.
   
B.The Landlord and the Tenant desire to extend the term of the Original Lease, alter the Base Rent payable under the Original Lease and to make other amendments to the Lease as provided in this Second Amendment.

 

AGREEMENT

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are acknowledged, the Landlord and the Tenant covenant and agree as follows:

 

1.LEASE TERM. Tenant wishes to extend the term of the Lease for a period of two (2) years (the “Renewal Lease Term”) commencing on February 1, 2026, so that the Renewal Lease Term will expire on January 31, 2028.
   
2.RENT. Tenant shall pay three-thousand six-hundred eighty-eight and no/100 dollars ($3,688.00) per month from February 1, 2026 through January 31, 2027; three-thousand seven-hundred ninety-eight and 64/100 dollars ($3,798.64) per month from February 1, 2027 through January 31, 2028 during the Renewal Lease Term.
   
3.OPERATING EXPENSES. The Tenant shall continue to pay Tenant’s Pro Rata Share, currently at 14.91%, of Operating Expenses in the manner provided in the Lease.
   
4.LANDLORD WORK. The Tenant accepts the Premises in their “as-is” condition, and the Tenant is not entitled to any improvement by the Landlord or to any other allowance, concession, or credit from Landlord for improvements.
   
5.STATUS OF LEASE OBLIGATIONS. The Tenant acknowledges and certifies that as of the date hereof, the Landlord has performed all covenants and obligations on the part of the Landlord to be performed under the Lease and that the Tenant has no claims or right of offset against the Landlord or the rentals reserved under the Original Lease as amended by this Second Amendment.
   
6.RATIFICATION. The Tenant ratifies and confirms the Lease as amended this Second Amendment. Except as amended this Second Amendment, all of the terms and conditions of the Lease shall remain in full force and effect.
   
7.SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon and shall inure to the benefit of the heirs, personal representatives, successors, and permitted assigns of the respective parties hereto.
   
8.COUNTERPARTS; ELECTRONIC SIGNATURES. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. The parties agree that signatures transmitted electronically shall be binding as if they were original signatures.

 

 

 

 

 

 1 

 

 

 

Lease Extension Agreement

 

 

IN WITNESS WHEREOF, the Landlord and the Tenant have executed this Second Amendment as of the day and year first above written.

 

 

LANDLORD:

   TENANT:
     
WESTLAND DEVELOPMENT SERVICES, INC.,   SONOMA PHARMACEUTICALS, INC.
a Colorado Corporation   a Delaware Corporation
     
By: /s/ Peter Aweida   By: /s/ Amy Trombly
     
Name: Peter Aweida   Name: Amy Trombly
     
Title: President   Title: Chief Executive Officer
     
Date: November 11, 2025   Date: November 10, 2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 2 

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer